9.6/10 on Trustpilot with 47k+ reviews!
Apoquel
3.6mg Tablets » Priced per tablet
5.4mg Tablets » Priced per tablet
16mg Tablets » Priced per tablet

  • 3.6mg Tablets » Priced per tablet £0.70
  • 5.4mg Tablets » Priced per tablet £0.70
  • 16mg Tablets » Priced per tablet £1.40

Selection of 3 products from

£0.70 to £1.40

Description

This product is sourced in the United Kingdom and is intended for use in the United Kindgom only.

Apoquel is an extremely promising new drug aimed at treating the discomfort which is seen in allergic skin disease, especially when that relates to airborne or environmental allergens. Early reports on its use are especially encouraging and sometimes quite dramatic. Vets will prescribe it particularly to treat atopic dermatitis or atopy, which is a common cause if itchiness and discomfort found in dogs which are reacting to house dust and house dust mites, as well as other triggers of allergic skin disease found in the environment. Apoquel can also be used to reduce the itching seen in dogs with other forms of skin allergy, but food elimination trials and treating for parasites (particularly fleas) is strongly recommended. It is also important to make sure that no skin infection is present, so a course of antibiotic might be given too.

Apoquel tablets are given twice daily initially, reducing to once daily after 14 days. Quite often a short course of tablets is all that is needed to control symptoms, but some dogs will go onto once daily dosing for a much longer period. Apoquel tablets suppress a specific part of the immune response in order to work. This is not usually associated with any side effects, but it is possible to see vomiting and diarrhoea, as well as a number of other effects. It is possible that the response to vaccination might be reduced if a vaccine is given while Apoquel tablets are being taken. These factors need to be taken into account, especially if long term use is intended.

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

16mg Tablets » Priced per tablet

Apoquel film-coated tablets for dogs

Presentation

Apoquel tablets contain 3.6, 5.4 or 16 mg oclacitinib (as oclacitinib maleate). Each tablet is marked with “AQ” on one side, with “S”, “M” or “L” on the other side referring to the tablet strengths.

Uses

Indicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.

Dosage and administration

For oral use.

Dosage and treatment schedule

The recommended initial dose is 0.4 to 0.6 mg oclacitinib/kg bodyweight, administered orally, twice daily for up to 14 days.

For maintenance therapy, the same dose (0.4 to 0.6 mg oclacitinib/kg bodyweight) should then be administered only once a day. The requirement for long-term maintenance therapy should be based on an individual benefit-risk assessment.

Apoquel can be administered with or without food.

The dosing table below shows the number of tablets required. The tablets are breakable along the score line.

Contra-indications, warnings, etc

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs less than 12 months of age or less than 3 kg bodyweight.

Do not use in dogs with evidence of immune suppression, such as hyperadrenocorticism, or with evidence of progressive malignant neoplasia as the active substance has not been evaluated in these cases.

The safety of Apoquel during pregnancy, lactation or in dogs intended for breeding has not been established, so its use is not recommended.

Oclacitinib modulates the immune system and may increase susceptibility to infection and exacerbate neoplastic conditions. Dogs receiving APOQUEL tablets should therefore be monitored periodically with complete blood counts and serum biochemistry when on long-term treatment.

When treating pruritus associated with allergic dermatitis with oclacitinib, investigate and treat any underlying causes (e.g. flea allergic dermatitis, contact dermatitis, food hypersensitivity). Furthermore, in cases of allergic dermatitis and atopic dermatitis, it is recommended to investigate and treat complicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g. flea and mange).

The common adverse reactions seen up to day 16 of the field trials are listed in the following table:

After day 16, the following have been observed:

The frequency of adverse reactions is defined using the following convention:

Treatment related clinical pathology changes were restricted to an increase in mean serum cholesterol and a decrease in mean leukocyte count, however, all mean values remained within the laboratory reference range. The decrease in mean leukocyte count observed in oclacitinib-treated dogs was not progressive, and affected all white blood cell counts (neutrophil, eosinophil and monocyte counts) except lymphocyte counts. Neither of these clinical pathology changes appeared clinically significant.In a laboratory study, the development of papillomas was noted in a number of dogs.

No drug interactions were observed in field studies where oclacitinib was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials and anti-inflammatories.

The impact of oclacitinib administration on vaccination with modified live vaccines, canine parvovirus (CPV), canine distemper virus (CDV) and canine parainfluenza (CPI) and inactivated rabies vaccine (RV), on 16 week old vaccine naïve puppies has been studied. An adequate immune response (serology) to CDV and CPV vaccination was achieved when puppies were administered oclacitinib at 1.8 mg/kg bodyweight twice daily for 84 days. However, the findings of this study indicated a reduction in serological response to vaccination with CPI and RV in puppies being treated with oclacitinib compared to untreated controls. The clinical relevance of these observed effects for animals vaccinated while being administered oclacitinib (in accordance with the recommended dosing regimen) is unclear.

Oclacitinib tablets were administered at 1x, 3x and 5x to healthy, one year old Beagle dogs twice daily for 6 weeks followed by once daily for 20 weeks.

Clinical observations that were considered likely to be related to oclacitinib treatment included: alopecia (local), papilloma, dermatitis, erythema, abrasions and scabbing/crusts, interdigital "cysts", and oedema of the paws. Dermatitis lesions were mostly secondary to the development of interdigital furunculosis on one or more paws during the study, with the number and frequency of observations increased with increasing dose. Lymphadenopathy of peripheral nodes was noted in all groups, increasing in frequency with increased dose, and was frequently associated with interdigital furunculosis. Papilloma was considered treatment related, but not dose related.

There is no specific antidote and in case of signs of overdose the dog should be treated symptomatically.

User warnings

Wash hands after administration.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the doctor.

Pharmaceutical precautions

Store below 25°C.

Any remaining half tablet should be placed back in the opened blister and stored in the original cardboard carton or in the HDPE bottle (for a maximum of 3 days).

Do not use after the expiry date which is stated on the blister or carton.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Keep out of the sight and reach of children.

For animal treatment only.

Legal category

Packaging quantities

Supplied in blister strips (each strip containing 10 film-coated tablets) or HDPE plastic bottles. Pack sizes of 20, 50 or 100 tablets. Not all pack sizes may be marketed.

Further information

Oclacitinib is a Janus kinase (JAK) inhibitor. It can inhibit the function of a variety of cytokines dependent on JAK enzyme activity. For oclacitinib, the target cytokines are those that are proinflammatory or have a role in allergic responses/pruritis.

Following oral administration in dogs, oclacitinib maleate is rapidly and well absorbed, with a time to peak plasma concentration (tmax) of less than 1 hour. The absolute bioavailability of oclacitinib maleate was 89%.

Total body oclacitinib clearance from plasma was low; 316 ml/h/kg bodyweight (5.3 ml/min/kg bodyweight), and the apparent volume of distribution at steady-state was 942 ml/kg bodyweight. Following intravenous and oral administration, the half-lives were similar at 3.5 and 4.1 hours respectively. Oclacitinib exhibits low protein binding.

Overall the major clearance route is metabolism, with minor contributions from renal and biliary elimination. Inhibition of canine cytochrome P450s is minimal. Therefore, the risk of metabolic drug-drug interactions due to oclacitinib inhibition is very low. No accumulation was observed in the blood of dogs treated for 6 months with oclacitinib.

Marketing Authorisation Number

EU/2/13/154/001-018

3.6mg Tablets » Priced per tablet

Apoquel film-coated tablets for dogs

Presentation

Apoquel tablets contain 3.6, 5.4 or 16 mg oclacitinib (as oclacitinib maleate). Each tablet is marked with “AQ” on one side, with “S”, “M” or “L” on the other side referring to the tablet strengths.

Uses

Indicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.

Dosage and administration

For oral use.

Dosage and treatment schedule

The recommended initial dose is 0.4 to 0.6 mg oclacitinib/kg bodyweight, administered orally, twice daily for up to 14 days.

For maintenance therapy, the same dose (0.4 to 0.6 mg oclacitinib/kg bodyweight) should then be administered only once a day. The requirement for long-term maintenance therapy should be based on an individual benefit-risk assessment.

Apoquel can be administered with or without food.

The dosing table below shows the number of tablets required. The tablets are breakable along the score line.

Contra-indications, warnings, etc

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs less than 12 months of age or less than 3 kg bodyweight.

Do not use in dogs with evidence of immune suppression, such as hyperadrenocorticism, or with evidence of progressive malignant neoplasia as the active substance has not been evaluated in these cases.

The safety of Apoquel during pregnancy, lactation or in dogs intended for breeding has not been established, so its use is not recommended.

Oclacitinib modulates the immune system and may increase susceptibility to infection and exacerbate neoplastic conditions. Dogs receiving APOQUEL tablets should therefore be monitored periodically with complete blood counts and serum biochemistry when on long-term treatment.

When treating pruritus associated with allergic dermatitis with oclacitinib, investigate and treat any underlying causes (e.g. flea allergic dermatitis, contact dermatitis, food hypersensitivity). Furthermore, in cases of allergic dermatitis and atopic dermatitis, it is recommended to investigate and treat complicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g. flea and mange).

The common adverse reactions seen up to day 16 of the field trials are listed in the following table:

After day 16, the following have been observed:

The frequency of adverse reactions is defined using the following convention:

Treatment related clinical pathology changes were restricted to an increase in mean serum cholesterol and a decrease in mean leukocyte count, however, all mean values remained within the laboratory reference range. The decrease in mean leukocyte count observed in oclacitinib-treated dogs was not progressive, and affected all white blood cell counts (neutrophil, eosinophil and monocyte counts) except lymphocyte counts. Neither of these clinical pathology changes appeared clinically significant.In a laboratory study, the development of papillomas was noted in a number of dogs.

No drug interactions were observed in field studies where oclacitinib was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials and anti-inflammatories.

The impact of oclacitinib administration on vaccination with modified live vaccines, canine parvovirus (CPV), canine distemper virus (CDV) and canine parainfluenza (CPI) and inactivated rabies vaccine (RV), on 16 week old vaccine naïve puppies has been studied. An adequate immune response (serology) to CDV and CPV vaccination was achieved when puppies were administered oclacitinib at 1.8 mg/kg bodyweight twice daily for 84 days. However, the findings of this study indicated a reduction in serological response to vaccination with CPI and RV in puppies being treated with oclacitinib compared to untreated controls. The clinical relevance of these observed effects for animals vaccinated while being administered oclacitinib (in accordance with the recommended dosing regimen) is unclear.

Oclacitinib tablets were administered at 1x, 3x and 5x to healthy, one year old Beagle dogs twice daily for 6 weeks followed by once daily for 20 weeks.

Clinical observations that were considered likely to be related to oclacitinib treatment included: alopecia (local), papilloma, dermatitis, erythema, abrasions and scabbing/crusts, interdigital "cysts", and oedema of the paws. Dermatitis lesions were mostly secondary to the development of interdigital furunculosis on one or more paws during the study, with the number and frequency of observations increased with increasing dose. Lymphadenopathy of peripheral nodes was noted in all groups, increasing in frequency with increased dose, and was frequently associated with interdigital furunculosis. Papilloma was considered treatment related, but not dose related.

There is no specific antidote and in case of signs of overdose the dog should be treated symptomatically.

User warnings

Wash hands after administration.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the doctor.

Pharmaceutical precautions

Store below 25°C.

Any remaining half tablet should be placed back in the opened blister and stored in the original cardboard carton or in the HDPE bottle (for a maximum of 3 days).

Do not use after the expiry date which is stated on the blister or carton.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Keep out of the sight and reach of children.

For animal treatment only.

Legal category

Packaging quantities

Supplied in blister strips (each strip containing 10 film-coated tablets) or HDPE plastic bottles. Pack sizes of 20, 50 or 100 tablets. Not all pack sizes may be marketed.

Further information

Oclacitinib is a Janus kinase (JAK) inhibitor. It can inhibit the function of a variety of cytokines dependent on JAK enzyme activity. For oclacitinib, the target cytokines are those that are proinflammatory or have a role in allergic responses/pruritis.

Following oral administration in dogs, oclacitinib maleate is rapidly and well absorbed, with a time to peak plasma concentration (tmax) of less than 1 hour. The absolute bioavailability of oclacitinib maleate was 89%.

Total body oclacitinib clearance from plasma was low; 316 ml/h/kg bodyweight (5.3 ml/min/kg bodyweight), and the apparent volume of distribution at steady-state was 942 ml/kg bodyweight. Following intravenous and oral administration, the half-lives were similar at 3.5 and 4.1 hours respectively. Oclacitinib exhibits low protein binding.

Overall the major clearance route is metabolism, with minor contributions from renal and biliary elimination. Inhibition of canine cytochrome P450s is minimal. Therefore, the risk of metabolic drug-drug interactions due to oclacitinib inhibition is very low. No accumulation was observed in the blood of dogs treated for 6 months with oclacitinib.

Marketing Authorisation Number

EU/2/13/154/001-018

5.4mg Tablets » Priced per tablet

Apoquel film-coated tablets for dogs

Presentation

Apoquel tablets contain 3.6, 5.4 or 16 mg oclacitinib (as oclacitinib maleate). Each tablet is marked with “AQ” on one side, with “S”, “M” or “L” on the other side referring to the tablet strengths.

Uses

Indicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.

Dosage and administration

For oral use.

Dosage and treatment schedule

The recommended initial dose is 0.4 to 0.6 mg oclacitinib/kg bodyweight, administered orally, twice daily for up to 14 days.

For maintenance therapy, the same dose (0.4 to 0.6 mg oclacitinib/kg bodyweight) should then be administered only once a day. The requirement for long-term maintenance therapy should be based on an individual benefit-risk assessment.

Apoquel can be administered with or without food.

The dosing table below shows the number of tablets required. The tablets are breakable along the score line.

Contra-indications, warnings, etc

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs less than 12 months of age or less than 3 kg bodyweight.

Do not use in dogs with evidence of immune suppression, such as hyperadrenocorticism, or with evidence of progressive malignant neoplasia as the active substance has not been evaluated in these cases.

The safety of Apoquel during pregnancy, lactation or in dogs intended for breeding has not been established, so its use is not recommended.

Oclacitinib modulates the immune system and may increase susceptibility to infection and exacerbate neoplastic conditions. Dogs receiving APOQUEL tablets should therefore be monitored periodically with complete blood counts and serum biochemistry when on long-term treatment.

When treating pruritus associated with allergic dermatitis with oclacitinib, investigate and treat any underlying causes (e.g. flea allergic dermatitis, contact dermatitis, food hypersensitivity). Furthermore, in cases of allergic dermatitis and atopic dermatitis, it is recommended to investigate and treat complicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g. flea and mange).

The common adverse reactions seen up to day 16 of the field trials are listed in the following table:

After day 16, the following have been observed:

The frequency of adverse reactions is defined using the following convention:

Treatment related clinical pathology changes were restricted to an increase in mean serum cholesterol and a decrease in mean leukocyte count, however, all mean values remained within the laboratory reference range. The decrease in mean leukocyte count observed in oclacitinib-treated dogs was not progressive, and affected all white blood cell counts (neutrophil, eosinophil and monocyte counts) except lymphocyte counts. Neither of these clinical pathology changes appeared clinically significant.In a laboratory study, the development of papillomas was noted in a number of dogs.

No drug interactions were observed in field studies where oclacitinib was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials and anti-inflammatories.

The impact of oclacitinib administration on vaccination with modified live vaccines, canine parvovirus (CPV), canine distemper virus (CDV) and canine parainfluenza (CPI) and inactivated rabies vaccine (RV), on 16 week old vaccine naïve puppies has been studied. An adequate immune response (serology) to CDV and CPV vaccination was achieved when puppies were administered oclacitinib at 1.8 mg/kg bodyweight twice daily for 84 days. However, the findings of this study indicated a reduction in serological response to vaccination with CPI and RV in puppies being treated with oclacitinib compared to untreated controls. The clinical relevance of these observed effects for animals vaccinated while being administered oclacitinib (in accordance with the recommended dosing regimen) is unclear.

Oclacitinib tablets were administered at 1x, 3x and 5x to healthy, one year old Beagle dogs twice daily for 6 weeks followed by once daily for 20 weeks.

Clinical observations that were considered likely to be related to oclacitinib treatment included: alopecia (local), papilloma, dermatitis, erythema, abrasions and scabbing/crusts, interdigital "cysts", and oedema of the paws. Dermatitis lesions were mostly secondary to the development of interdigital furunculosis on one or more paws during the study, with the number and frequency of observations increased with increasing dose. Lymphadenopathy of peripheral nodes was noted in all groups, increasing in frequency with increased dose, and was frequently associated with interdigital furunculosis. Papilloma was considered treatment related, but not dose related.

There is no specific antidote and in case of signs of overdose the dog should be treated symptomatically.

User warnings

Wash hands after administration.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the doctor.

Pharmaceutical precautions

Store below 25°C.

Any remaining half tablet should be placed back in the opened blister and stored in the original cardboard carton or in the HDPE bottle (for a maximum of 3 days).

Do not use after the expiry date which is stated on the blister or carton.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Keep out of the sight and reach of children.

For animal treatment only.

Legal category

Packaging quantities

Supplied in blister strips (each strip containing 10 film-coated tablets) or HDPE plastic bottles. Pack sizes of 20, 50 or 100 tablets. Not all pack sizes may be marketed.

Further information

Oclacitinib is a Janus kinase (JAK) inhibitor. It can inhibit the function of a variety of cytokines dependent on JAK enzyme activity. For oclacitinib, the target cytokines are those that are proinflammatory or have a role in allergic responses/pruritis.

Following oral administration in dogs, oclacitinib maleate is rapidly and well absorbed, with a time to peak plasma concentration (tmax) of less than 1 hour. The absolute bioavailability of oclacitinib maleate was 89%.

Total body oclacitinib clearance from plasma was low; 316 ml/h/kg bodyweight (5.3 ml/min/kg bodyweight), and the apparent volume of distribution at steady-state was 942 ml/kg bodyweight. Following intravenous and oral administration, the half-lives were similar at 3.5 and 4.1 hours respectively. Oclacitinib exhibits low protein binding.

Overall the major clearance route is metabolism, with minor contributions from renal and biliary elimination. Inhibition of canine cytochrome P450s is minimal. Therefore, the risk of metabolic drug-drug interactions due to oclacitinib inhibition is very low. No accumulation was observed in the blood of dogs treated for 6 months with oclacitinib.

Marketing Authorisation Number

EU/2/13/154/001-018

Delivery Information

How quickly do you deliver?

Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.

What do you charge for delivery?

For UK delivery, we charge the following:

Order Total Weight Delivery
£0-£28.99 Under 2kg £2.99
2kg+ £4.99
£29-£38.99 Under 2kg Free
2kg+ £4.99
£39+ Under 2kg Free
2kg+ Free

Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.

For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.

We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.

Delivery of aerosols

Due to air freight restrictions aerosols cannot ever be sent abroad by Royal Mail. We appreciate your understanding.

Delivery of temperature controlled items

Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.

How do I cancel or return an order?

Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.

To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.

*For full details on returns, see our terms and conditions page.

Reviews (262)

Q & A

Below are some recent questions we've received regarding Apoquel, including answers from our team.

21 May 2018 at 5:41pm

V A T

Sheena Ashford

Are your prices include VAT .

  • Customer Service Advisor

Hi Sheena,

Thank you for your question.

Yes, all prices include VAT.

Hope that helps,

VioVet.

15 September 2017 at 8:20am

Pricing Structure

Faye Mackay

  • VioVet customer since 2017
  • From: Aberdeenshire, United Kingdom

Hi, just to make it clear to myself.
The apoquel 16mg is £1.40 for 1.

Is that 1 tablet or 1 bottle?
Kind regards, Faye.

  • Website Content Developer

Hi Faye,

Thank you for the question.

It is £1.40 per 16mg tablet of Apoquel.

6 October 2016 at 9:17pm

Gary Chisholm

  • VioVet customer since 2009
  • From: , United Kingdom

Hi my dog was on Atopica for a year due to the lack of Apoquel in the U.K.
He has been on them for 5 weeks at 2 times 3.6mg tablets I asked to continue the loading dose of 2 a day as he was struggling with itching excessive paw licking and spinning on his bottom all symptoms of his Alergys.
They seem to be working but just not as well as I hoped , it's almost like there not quite strong enough.
He weighs 12.8 kg what dosage should he be on? I'm still giving him 2 a day as I know once I drop to just one 3.6 he will suffer .??
Kind regards
Gary

  • Veterinary Advisor

The recommended dosage is 0.4-0.6mg apoquel/kg bodyweight twice daily for 14 days then once daily thereafter for maintenance. This would work out at 5.12-7.68mg once daily for a 12.8kg dog on the maintenance dose. It would therefore be ok for him to continue on two 3.6mg tablets once a day or one 5.4mg tablet once a day. However you should consult your vet regarding the dose your dog is on as there is likely to be a reason that the current dose rate has been prescribed.

30 July 2016 at 7:56pm

Dogs warmer than normal

Donna Beasley

  • VioVet customer since 2016
  • From: California, United States

One of my Dogs seems to be Warm since taking Apoquel, is that normal?

  • Non-Executive Director

Has his internal body temperature increased (as confirmed by thermometer)? I presume not and that you mean his skin feels warmer to the touch. If so, then this is difficult to measure accurately and indeed is often caused by the underlying problem Apoquel is trying to prevent, as well as many other things. This is not something I would expect to be caused by the Apoquel at all, but if you are unsure, you should see your vet about it.

11 June 2016 at 11:56pm

Echinacea and nettle for dogs

Laura Chivers

  • VioVet customer since 2014
  • From: Devon, United Kingdom

Can I give my dog the chudleys echinacea and nettle with daily apoquel? I want to build his immunity up and look for long term solutions.

  • Non-Executive Director

It should be perfectly OK to give Chudleys Echinacea with Apoquel. How effective it will be in modulating the immune response to things is not known, but it should be fine to try.

23 September 2015 at 10:10pm

Do you have any apoquel 16 mg in??

Denise Esler

  • VioVet customer since 2015
  • From: Minnesota, United States

I desperately need apoquel for my dog. Says out of stock but then says limited stock. What would be the price in us dollars?? She takes 1 & 1/ 2 per day.

  • Non-Executive Director

We generally do have a few of these for sale now, but they are in limited supply. If you buy them from the USA, in US dollars then you will pay about one and a half times the price as listed on our website in Great Britain Pounds. There is also a delivery charge of £10 which is about £15 dollars. So if you bought 100 of the 5.4mg tablets, they would cost about $160 altogether. (The price will vary slightly depending on the exchange rate between dollars and pounds.) You do also need to send us a written prescription from your vet authorising the tablets you want to buy. You can email us a copy of the prescription. (I expect the price will come down in future, as tablets become more widely available.)

19 August 2015 at 8:08am

Apoquel

Shazza

My dog has made very good progress on these tablets and my vet can't get any at moment, what is the next best thing for her to stop scratching?????

  • Non-Executive Director

This is a question for your own vet really. There are other prescription medicines but they are usually much less good than Apoquel. There are various shampoos and food supplements (mostly based on fish and vegetable oils) which help a bit. I would recommend Yumega Plus for any dog like this, along with any mild dog shampoo (Oatmeal and Alow vera seem to help a bit).

7 February 2015 at 5:19pm

Can my dog use turmeric with apoquel?

Marie Pygott

  • VioVet customer since 2014
  • From: East Riding of Yorkshire, United Kingdom

Hi, my dog is currently using Apoquel to successfully manage allergies, I'd like to start him on turmeric (golden paste) turmeric/black pepper/cold pressed coconut oil. It's a natural remedy used for arheritis. I just want to check that is safe with Apoquel. Many thankd

  • Non-Executive Director

I would expect this to be perfectly safe. Apoquel is a relatively new drug and so there has not been enough time for all possible interactions with other products to have been reported, but it is highly unlikely to be a problem.

30 October 2014 at 10:21pm

Apoquel Rx

Rebecca Dixon

Hello
I have a dog whose been on Apoquel since the beginning oh 2014 I noticed that you are currently out of stock but also require a prescription I live in the U.S. Should I send you a prescription now to have on file? Will you fill my order once it's back in stock or will you notify when it is in stock for me to place an order at that time? I realize the drug is hard to come by and in demand just hoping to be proactive in acquiring the drug Can you tell me when you think your next shipment will be?
Thank you in advance for your help
Rebecca Dixon

  • Non-Executive Director

I think that as soon as the manufacturer can produce more Apoquel, everyone will be able to get it at the same time. We are not expecting that to be before March 2015, but we live in hope. We have received so many requests for it that we cannot aim to follow them all up, but I am sure that you will know all about it when more product is available. Your best bet is to keep vigilant and look on the internet for news updates about it becoming available again. If any country or supplier gets it before the others, they will certainly make it known as soon as they can. My feeling is that it will be released across the USA and in the UK at the same time. If one beats the other for any reason, there will be advance notification of this because it is so eagerly awaited by everyone. We might start taking advance orders in anticipation of the launch, but it is far too premature to do that yet. We will know more about it all closer to the time. Meantime we have to be patient and try to manage atopic dogs as well as we can in other ways.

14 October 2014 at 4:55am

Do you have apoquel?

Karen murray

My dog has terrible allergies and responded well to Apoquel trial then drug was not available in US. Do you have any Apoquel?

  • Non-Executive Director

It is hugely disappointing that after producing such a great medication, the manufacturer has completely run out of stocks worldwide. They are frantically trying to make more but the production process is long and complicated. We will have more supplies early in 2015 but until then we do not expect to have any. Our own stocks ran out during the summer.